Wells Fargo & Company Checkpoint Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.02 - $10.6 $16 - $169	16 Added 3.47%	477 $0
Q2 2022 Aug 12, 2022	SELL	$0.97 - $1.77 $1,335 - $2,437	-1,377 Reduced 74.92%	461 $0
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $2,221 - $4,719	1,452 Added 376.17%	1,838 $3,000
Q4 2021 Feb 14, 2022	BUY	$2.68 - $4.46 $13 - $22	5 Added 1.31%	386 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.5 - $3.53 $45 - $63	-18 Reduced 4.51%	381 $1,000
Q2 2021 Aug 16, 2021	SELL	$2.36 - $3.2 $116,711 - $158,252	-49,454 Reduced 99.2%	399 $1,000
Q1 2021 May 13, 2021	SELL	$2.6 - $4.16 $227,702 - $364,324	-87,578 Reduced 63.73%	49,853 $157,000
Q4 2020 Feb 09, 2021	BUY	$2.19 - $2.96 $31,165 - $42,123	14,231 Added 11.55%	137,431 $364,000
Q3 2020 Nov 05, 2020	BUY	$1.62 - $4.24 $15,809 - $41,378	9,759 Added 8.6%	123,200 $330,000
Q2 2020 Aug 13, 2020	BUY	$1.19 - $2.27 $89,484 - $170,697	75,197 Added 196.62%	113,441 $224,000
Q1 2020 May 14, 2020	BUY	$1.11 - $2.43 $42,450 - $92,932	38,244 New	38,244 $57,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.